Image-derived biomarkers and multimodal imaging strategies for lung cancer management.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25573632.
- Also identified by DOI 10.1007/s00259-014-2974-5.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Non-small-cell lung cancer is the most common type of lung cancer and one of the leading causes of cancer-related death worldwide. For this reason, advances in diagnosis and treatment are urgently needed. With the introduction of new, highly innovative hybrid imaging technologies such as PET/CT, staging and therapy response monitoring in lung cancer patients have substantially evolved. In this review, we discuss the role of FDG PET/CT in the management of lung cancer patients and the importance of new emerging imaging technologies and radiotracer developments on the path to personalized medicine.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Multimodal Imaging
- Positron-Emission Tomography
- Radiopharmaceuticals